TNFRSF9 and neoplasm: Therefore, the use of PD-1 as a single marker to screen for TSTs may be controversial and it is not possible to identify universally applicable markers due to differences in tumor types, whereas PD-1+CD137+CD8+ T cells are supposed to be a highly tumor-specific responsive T cell population.